NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $0.63 +0.01 (+1.88%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.62 0.00 (-0.51%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CytomX Therapeutics Stock (NASDAQ:CTMX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytomX Therapeutics alerts:Sign Up Key Stats Today's Range$0.59▼$0.6350-Day Range$0.59▼$0.9452-Week Range$0.56▼$5.85Volume832,081 shsAverage Volume2.64 million shsMarket Capitalization$50.32 millionP/E Ratio3.70Dividend YieldN/APrice Target$5.02Consensus RatingModerate Buy Company OverviewCytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More… Remove Ads CytomX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreCTMX MarketRank™: CytomX Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 148th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about CytomX Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.05) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is 3.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.58.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is 3.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.60.Read more about CytomX Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.37% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 91.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.74 Percentage of Shares Shorted12.37% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 91.49%, indicating that investor sentiment is decreasing significantly. News and Social Media3.9 / 5News Sentiment0.94 News SentimentCytomX Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for CTMX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,968.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Stock News HeadlinesInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of StockMarch 21, 2025 | insidertrades.comCytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal yearMarch 14, 2025 | uk.investing.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. March 30, 2025 | Paradigm Press (Ad)CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comCytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy NowMarch 7, 2025 | insidermonkey.comCytomX Therapeutics Announces 2024 Financial Results and Provides Business UpdateMarch 7, 2025 | markets.businessinsider.comCytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comCytomX Therapeutics Announces 2024 Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comSee More Headlines CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $1.03 at the start of the year. Since then, CTMX stock has decreased by 39.0% and is now trading at $0.6282. View the best growth stocks for 2025 here. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings results on Thursday, March, 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.45. The biotechnology company earned $38.09 million during the quarter, compared to analysts' expectations of $13.53 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 41.47% and a net margin of 10.96%. Who are CytomX Therapeutics' major shareholders? Top institutional shareholders of CytomX Therapeutics include Tang Capital Management LLC (9.34%), Prosight Management LP (4.99%), Millennium Management LLC (4.12%) and Point72 Asset Management L.P. (3.39%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Christopher Ogden, Lloyd A Rowland, Jeffrey B Landau, Amy C Peterson, Carlos Campoy and Elaine V Jones. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), CymaBay Therapeutics (CBAY), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings3/06/2025Today3/30/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTMX CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees170Year FoundedN/APrice Target and Rating Average Stock Price Target$5.02 High Stock Price Target$8.00 Low Stock Price Target$3.50 Potential Upside/Downside+699.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.38 Trailing P/E Ratio3.70 Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,000.00 Net Margins10.96% Pretax Margin11.89% Return on Equity-41.47% Return on Assets8.11% Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio1.04 Sales & Book Value Annual Sales$138.10 million Price / Sales0.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-0.88Miscellaneous Outstanding Shares80,100,000Free Float72,781,000Market Cap$50.32 million OptionableOptionable Beta1.05 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:CTMX) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredMan Who Predicted 2008 Crash: “Move your money out of stocks TODAY”Could the recent tech sell-off indicate a looming market crash? Nvidia dropped 30% from its high... Pala...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.